Top

Published in:

01-06-2017 | Neurology and Preclinical Neurological Studies - Short communication

Parkinson’s disease as a multisystem disorder

Authors: Lisa Klingelhoefer, H. Reichmann

Published in: Journal of Neural Transmission | Issue 6/2017

Abstract

This article summarises the noteworthy contribution of Professor Jellinger to the understanding of Parkinson’s disease (PD) as a disease affecting multiple body- and neurotransmitter-systems. Phosphorylated alpha-synuclein and the formation of Lewy pathology as neuropathological hallmarks of PD seem to spread from the enteric nervous system and the olfactory bulb in a rostrocranial direction to the CNS. Subsequently, a progressive degeneration of the dopaminergic–nigrostriatal system and widespread extranigral pathology affecting different anatomical structures and neurotransmitters are induced causing the various non-motor and motor symptoms of PD.

Abbott RD, Petrovitch H et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3):456–462CrossRefPubMed

Attems J, Jellinger KA (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol 34(4):466–467CrossRefPubMed

Beach TG, Adler CH et al (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119(6):689–702CrossRefPubMedPubMedCentral

Boeve BF (2010) REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 1184:15–54CrossRefPubMedPubMedCentral

Bottner M, Zorenkov D et al (2012) Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 48(3):474–480CrossRefPubMed

Braak H, Braak E et al (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88(6):493–500CrossRefPubMed

Braak H, Del Tredici K et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed

Braak H, Bohl JR et al (2006a) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21(12):2042–2051CrossRefPubMed

Braak H, de Vos RA et al (2006b) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72CrossRefPubMed

Cersosimo MG, Benarroch EE (2008) Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23(8):1065–1075CrossRefPubMed

Cersosimo MG, Raina GB et al (2013) Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 260(5):1332–1338CrossRefPubMed

Chaudhuri KR, Martinez-Martin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923CrossRefPubMed

Del Tredici K, Braak H (2016) Review: sporadic Parkinson’s disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33–50CrossRefPubMed

Del Tredici K, Hawkes CH et al (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119(6):703–713CrossRefPubMed

Dickson DW, Fujishiro H et al (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115(4):437–444CrossRefPubMed

Dickson DW, Uchikado H et al (2010) Evidence in favor of Braak staging of Parkinson’s disease. Mov Disord 25(Suppl 1):S78–S82CrossRefPubMed

Doty RL (2012) Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 8(6):329–339CrossRefPubMed

Drolet RE, Cannon JR et al (2009) Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiol Dis 36(1):96–102CrossRefPubMed

Erro R, Vitale C et al (2013) The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 8(8):e70244CrossRefPubMedPubMedCentral

Forman MS, Trojanowski JQ et al (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10(10):1055–1063CrossRefPubMed

Franco-Iborra S, Vila M et al (2015) The Parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist 22(3):266–277

Gallegos S, Pacheco C et al (2015) Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci 9:59CrossRefPubMedPubMedCentral

Gao HM, Hong JS et al (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 23(4):1228–1236PubMed

Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51(6):745–752CrossRefPubMedPubMedCentral

Greene JG, Noorian AR et al (2009) Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson’s disease. Exp Neurol 218(1):154–161CrossRefPubMedPubMedCentral

Haehner A, Hummel T et al (2009) Olfactory dysfunction as a diagnostic marker for Parkinson’s disease. Expert Rev Neurother 9(12):1773–1779CrossRefPubMed

Halliday G, McCann H et al (2012) Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother 12(6):673–686CrossRefPubMed

Hawkes CH, Del Tredici K et al (2010) A timeline for Parkinson’s disease. Parkinsonism Relat Disord 16(2):79–84CrossRefPubMed

Hughes AJ, Daniel SE et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral

Inden M, Kitamura Y et al (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 101(6):1491–1504CrossRefPubMed

Iranzo A, Molinuevo JL et al (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5(7):572–577CrossRefPubMed

Jankovic J, McDermott M et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534CrossRefPubMed

Jellinger KA (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14(3):153–197CrossRefPubMed

Jellinger KA (2003a) Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study. Acta Neuropathol 106(3):191–201CrossRefPubMed

Jellinger KA (2003b) General aspects of neurodegeneration. J Neural Transm 65(Suppl):101–144CrossRef

Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111(10–11):1219–1235CrossRefPubMed

Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) 116(9):1111–1162CrossRef

Jellinger KA (2011) Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 310(1–2):107–111CrossRefPubMed

Jellinger KA (2015a) How close are we to revealing the etiology of Parkinson’s disease? Expert Rev Neurother 15(10):1105–1107CrossRefPubMed

Jellinger KA (2015b) Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna) 122(10):1429–1440CrossRef

Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36 (discussion S36–S38) CrossRefPubMed

Jost WH (2010) Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci 289(1–2):69–73CrossRefPubMed

Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465):45–51CrossRefPubMedPubMedCentral

Kalaitzakis ME, Graeber MB et al (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34(3):284–295CrossRefPubMed

Kim YK, Yoon IY et al (2010) The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol 17(3):487–492CrossRefPubMed

Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors. Nat Rev Neurol 11(11):625–636CrossRefPubMed

Klingelhoefer L, Sokolov E et al (2014) Therapeutic options for nocturnal problems in Parkinson’s disease and atypical parkinsonian disorders. J Neural Transm (Vienna) 121(Suppl 1):S25–S31CrossRef

Lebouvier T, Neunlist M et al (2010) Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE 5(9):e12728CrossRefPubMedPubMedCentral

Marras C, Chaudhuri KR (2016) Nonmotor features of Parkinson’s disease subtypes. Mov Disord 31(8):1095–1102CrossRefPubMed

Martinez-Martin P, Schapira AH et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11):1623–1629CrossRefPubMed

McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S3–S7CrossRefPubMed

Mizuno Y, Ohta S et al (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163(3):1450–1455CrossRefPubMed

Mollenhauer B, Trautmann E et al (2013) Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81(14):1226–1234CrossRefPubMed

Muntane G, Ferrer I et al (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106–119CrossRefPubMed

Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3(8):591–605CrossRefPubMed

Pan-Montojo F, Anichtchik O et al (2010) Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5(1):e8762CrossRefPubMedPubMedCentral

Parkkinen L, Pirttila T et al (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115(4):399–407CrossRefPubMedPubMedCentral

Pfeiffer RF (2011) Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 17(1):10–15CrossRefPubMed

Phillips RJ, Walter GC et al (2008) Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience 153(3):733–750CrossRefPubMedPubMedCentral

Pont-Sunyer C, Hotter A et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30(2):229–237CrossRefPubMed

Postuma RB, Pelletier A et al (2016) Screening for prodromal Parkinson’s disease in the general community: a sleep-based approach. Sleep Med 21:101–105CrossRefPubMed

Reijnders JS, Ehrt U et al (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382CrossRefPubMed

Rodriguez M, Rodriguez-Sabate C et al (2015) Parkinson’s disease as a result of aging. Aging Cell 14(3):293–308CrossRefPubMedPubMedCentral

Sauerbier A, Jenner P et al (2016) Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S41–S46CrossRefPubMed

Savica R, Carlin JM et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73(21):1752–1758CrossRefPubMedPubMedCentral

Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3(6):362–368CrossRefPubMed

Schiess MC, Zheng H et al (2000) Parkinson’s disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 6(2):69–76CrossRefPubMed

Schrag A, Horsfall L et al (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14(1):57–64CrossRefPubMed

Schulz-Schaeffer WJ (2015) Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s disease? Biomolecules 5(3):1467–1479CrossRefPubMedPubMedCentral

Singaram C, Ashraf W et al (1995) Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 346(8979):861–864CrossRefPubMed

Titova N, Padmakumar C et al (2016) Parkinson’s: a syndrome rather than a disease? J Neural Transm. doi:10.1007/s00702-016-1667-6

Vilchez D, Saez I et al (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 5:5659CrossRefPubMed

Visanji NP, Marras C et al (2015) Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 84(6):609–616CrossRefPubMedPubMedCentral

Zaccai J, Brayne C et al (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70(13):1042–1048CrossRefPubMed

Zis P, Erro R et al (2015) The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review. npj Parkinson’s Dis 1, Art no: 15013

Title: Parkinson’s disease as a multisystem disorder
Authors: Lisa Klingelhoefer
H. Reichmann
Publication date: 01-06-2017
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 6/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-017-1692-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Parkinson’s disease as a multisystem disorder

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts

The "Madness" of Friedrich Hölderlin: an iatrogenic intoxication

Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson’s disease: historical overview and future prospects

Alzheimer’s senile plaque as shown by microcryodissection, a new technique for dissociating tissue structures

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects

Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease